Results 11 to 20 of about 70,715 (255)

Covalent Modification of the JH2 Domain of Janus Kinase 2. [PDF]

ACS Med Chem Lett, 2022
Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Henry SP, Liosi ME, Ippolito JA, Menges F, Newton AS, Schlessinger J, Jorgensen WL.   +6 more
europepmc   +3 more sources

The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate [PDF]

eLife, 2023
Class 1 cytokine receptors transmit signals through the membrane by a single transmembrane helix to an intrinsically disordered cytoplasmic domain that lacks kinase activity. While specific binding to phosphoinositides has been reported for the prolactin
Raul Araya-Secchi, Katrine Bugge, Pernille Seiffert, Amalie Petry, Gitte W Haxholm, Kresten Lindorff-Larsen, Stine Falsig Pedersen, Lise Arleth, Birthe B Kragelund   +8 more
doaj   +2 more sources

-escin mitigates neuroinflammation and apoptosis caused by ischemic stroke through the inhibition of the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway [PDF]

Journal of International Medical Research
Objective This study aimed to investigate the protective effects of β-escin against neuroinflammatory injury and its influence on the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of ...
Duan Yanqin, Liu Shenglan, Zhang Yu, Deng Yu, Du Qing, Zeng Hongliang, Tan Dianbo, Liu Chunhai, Yin yong, Liu Dongliang   +9 more
doaj   +2 more sources

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

Postgraduate Medicine, 2013
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovšek
exaly   +3 more sources

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Journal of Experimental Pharmacology, 2016
Jack W Singer,1 Suliman Al-Fayoumi,1 Haiching Ma,2 Rami S Komrokji,3 Ruben Mesa,4 Srdan Verstovsek5 1Translational Medicine, CTI BioPharma Corp., Seattle, WA, 2Department of Research and Development, Reaction Biology, Malvern, PA, 3Department of ...
Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S   +5 more
doaj   +4 more sources

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm [PDF]

South Asian Journal of Cancer, 2017
Context: Alterations in megakaryocyte morphology are the hallmark of myeloproliferative neoplasms (MPNs). These neoplasm are also associated with Janus kinase 2 (JAK2) V617F mutation in nearly 95% patients with polycythemia vera (PV), 40% patients of ...
Shuchi Ghai, Sharada Rai
doaj   +3 more sources

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

Frontiers in Medicine, 2023
Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues.
Dionysis Nikolopoulos, Dionysis Nikolopoulos, Ioannis Parodis, Ioannis Parodis, Ioannis Parodis   +4 more
doaj   +3 more sources

Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor [PDF]

Tzu Chi Medical Journal, 2019
Polycythemia vera (PV) is relatively uncommon in early adulthood, and evidence about the prevalence of the Janus kinase 2 (JAK2) V617F mutation in the general population is limited.
Shang-Hsien Yang, Hsiang-Lin Wan, Ming-Hui Gu, Tso-Fu Wang   +3 more
doaj   +2 more sources

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. [PDF]

Hepatology, 2023
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Torres S, Ortiz C, Bachtler N, Gu W, Grünewald LD, Kraus N, Schierwagen R, Hieber C, Meier C, Tyc O, Joseph Brol M, Uschner FE, Nijmeijer B, Welsch C, Berres ML, Garcia-Ruiz C, Fernandez-Checa JC, Trautwein C, Vogl TJ, Zeuzem S, Trebicka J, Klein S.   +21 more
europepmc   +2 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source